All roads led to Eko Hotels and Suites, Victoria Island, Lagos recently as the new and innovative La Roche Posay Mela B3 serum is launched amidst fun, cocktails and networking.
Formulated with a groundbreaking molecule patent by L’Oreal Dermatological Beauty Paris, the Mela B3 serum has an anti-relapse effect and noticeable difference in as short as one week. The product was lauded as a breakthrough solution meticulously crafted after almost two decades of research to address the challenges of hyperpigmentation faced by more than 50% of people, and without the common adverse effects of many depigmenting agents.
In her remarks, Mrs Beatrice Eneh, CEO of Ricks and Clare Solution, the company representing L’Oreal for its go-to-market and medical strategy in Nigeria, reiterated the importance of accessible and effective skincare solutions, tailored to the unique challenges of people in the African region.
A major highlight of the event graced by stakeholders from the healthcare sector was an interactive presentation by a consultant dermatologist, Dr Folakemi Cole-Adeife, who showcased the burden of hyperpigmentation, and transformative benefits of Mela B3.